IL285702B - Heterocyclic amides are useful as protein modulators - Google Patents
Heterocyclic amides are useful as protein modulatorsInfo
- Publication number
- IL285702B IL285702B IL285702A IL28570221A IL285702B IL 285702 B IL285702 B IL 285702B IL 285702 A IL285702 A IL 285702A IL 28570221 A IL28570221 A IL 28570221A IL 285702 B IL285702 B IL 285702B
- Authority
- IL
- Israel
- Prior art keywords
- protein modulators
- heterocyclic amides
- amides useful
- useful
- heterocyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319358P | 2016-04-07 | 2016-04-07 | |
| US201762461301P | 2017-02-21 | 2017-02-21 | |
| US201762461975P | 2017-02-22 | 2017-02-22 | |
| PCT/IB2017/051945 WO2017175147A1 (en) | 2016-04-07 | 2017-04-05 | Heterocyclic amides useful as protein modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL285702A IL285702A (en) | 2021-09-30 |
| IL285702B true IL285702B (en) | 2022-09-01 |
Family
ID=58503675
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL285702A IL285702B (en) | 2016-04-07 | 2017-04-05 | Heterocyclic amides are useful as protein modulators |
| IL261482A IL261482B (en) | 2016-04-07 | 2018-08-30 | Heterocyclic amides useful as protein modulators |
| IL261657A IL261657B (en) | 2016-04-07 | 2018-09-06 | Heterocyclic amides useful as protein modulators |
| IL295649A IL295649B2 (en) | 2016-04-07 | 2022-08-15 | Heterocyclic amides are useful as protein modulators |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL261482A IL261482B (en) | 2016-04-07 | 2018-08-30 | Heterocyclic amides useful as protein modulators |
| IL261657A IL261657B (en) | 2016-04-07 | 2018-09-06 | Heterocyclic amides useful as protein modulators |
| IL295649A IL295649B2 (en) | 2016-04-07 | 2022-08-15 | Heterocyclic amides are useful as protein modulators |
Country Status (33)
Families Citing this family (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034786B1 (ru) | 2015-08-13 | 2020-03-20 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные соединения в качестве агонистов sting |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| ES2929628T3 (es) | 2016-03-18 | 2022-11-30 | Immune Sensor Llc | Compuestos de dinucleótidos cíclicos y métodos de uso |
| UA123407C2 (uk) | 2016-04-07 | 2021-03-31 | Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед | Гетероциклічні аміди, придатні як модулятори протеїнів |
| SI3523287T1 (sl) | 2016-10-04 | 2021-11-30 | Merck Sharp & Dohme Corp. | Benzo(b)tiofenske spojine kot agonisti STING |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| IL269535B2 (en) | 2017-03-29 | 2024-11-01 | Ligachem Biosciences Inc | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same |
| EP3609922A2 (en) | 2017-04-13 | 2020-02-19 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| EP3661498A4 (en) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme Corp. | BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT |
| JP2020529421A (ja) | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ |
| WO2019069275A1 (en) * | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | STING AGONIST ADMINISTRATION METHODS |
| US11377440B2 (en) | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| TW201927771A (zh) * | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 可作為蛋白質調節劑之雜環醯胺及其使用方法 |
| PE20210156A1 (es) | 2017-11-10 | 2021-01-26 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3727401A4 (en) | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS |
| KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
| WO2019134707A1 (zh) * | 2018-01-08 | 2019-07-11 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN110016025B (zh) * | 2018-01-08 | 2021-08-06 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| JP2021513976A (ja) * | 2018-02-16 | 2021-06-03 | ユーシービー バイオファルマ エスアールエル | 医薬活性を有する６，５複素二環式環誘導体 |
| EP3768266A4 (en) * | 2018-03-20 | 2021-12-22 | Merck Sharp & Dohme Corp. | OXO-TETRAHYDRO-ISOCHINOLINE-CARBOXYLIC ACIDS AS STING INHIBITORS |
| IL309265A (en) | 2018-03-23 | 2024-02-01 | Codiak Biosciences Inc | Extracellular vesicles comprising sting-agonist |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| AU2019248545B2 (en) | 2018-04-03 | 2022-08-11 | Merck Sharp & Dohme Llc | Benzothiophenes and related compounds as sting agonists |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| MA52754A (fr) | 2018-05-25 | 2021-04-14 | Incyte Corp | Composés hétérocycliques tricycliques en tant qu'activateurs de sting |
| KR20210025016A (ko) | 2018-06-28 | 2021-03-08 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 접합 삼중고리형 헤테로사이클 화합물과 그 치료 용도 |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
| WO2020028566A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| EP3841112A1 (en) | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| KR102583738B1 (ko) | 2018-08-24 | 2023-09-26 | 애들레이 노르티 바이오파마 컴퍼니 리미티드 | 고 활성 sting 단백질 작용제 |
| JP7166028B2 (ja) * | 2018-08-29 | 2022-11-07 | アドライ・ノーティ・バイオファーマ・カンパニー・リミテッド | 高活性ｓｔｉｎｇタンパク質アゴニスト化合物 |
| CN112714649B (zh) | 2018-09-06 | 2024-07-02 | 第一三共株式会社 | 环状二核苷酸衍生物及其抗体药物偶联物 |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| ES2959804T3 (es) * | 2018-12-06 | 2024-02-28 | Glaxosmithkline Ip Dev Ltd | Nueva formulación farmacéutica que comprende un modulador de STING |
| JP2022511540A (ja) * | 2018-12-14 | 2022-01-31 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Ｓｔｉｎｇアゴニストとしての三環式化合物、ならびにその調製方法および医薬用途 |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| WO2020132566A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting pyrazole agonists and uses thereof |
| US12129267B2 (en) | 2019-01-07 | 2024-10-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| CN111471056B (zh) * | 2019-01-23 | 2021-07-02 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
| CN113563313B (zh) * | 2019-01-31 | 2022-11-04 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| CN113574063B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3133314A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicle conjugates and uses thereof |
| SG11202109702QA (en) | 2019-03-21 | 2021-10-28 | Codiak Biosciences Inc | Extracellular vesicles for vaccine delivery |
| CA3132508A1 (en) * | 2019-03-28 | 2020-10-01 | Lupin Limited | Macrocyclic compounds as sting agonists |
| TW202104214A (zh) | 2019-04-05 | 2021-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| WO2021000770A1 (zh) * | 2019-07-02 | 2021-01-07 | 凯复制药有限公司 | 可增强免疫活性的杂环化合物、其制备方法及其在医药上的应用 |
| WO2021003445A1 (en) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) * | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| DK4004002T3 (da) * | 2019-07-22 | 2024-09-30 | Lupin Ltd | Makrocykliske forbindelser som sting-agonister samt fremgangsmåder og anvendelser dermed |
| CN112279835B (zh) * | 2019-07-24 | 2022-07-22 | 中国医学科学院药物研究所 | 芳环或芳杂环并咪唑类化合物，其制备方法及制药用途 |
| WO2021013234A1 (en) | 2019-07-25 | 2021-01-28 | Beigene, Ltd. | Cyclic dinucleotides as sting agonists |
| CN112300227B (zh) * | 2019-07-25 | 2023-11-28 | 江西济民可信集团有限公司 | 杂环酰胺类化合物及其制备方法和应用 |
| TW202120500A (zh) * | 2019-08-02 | 2021-06-01 | 美商梅爾莎納醫療公司 | 干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途 |
| CN112521371B (zh) * | 2019-09-19 | 2022-11-25 | 中国药科大学 | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 |
| CN112521394A (zh) | 2019-09-19 | 2021-03-19 | 中国药科大学 | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 |
| EP4034276A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Methods of producing extracellular vesicles |
| EP4034150A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour |
| MX2022003570A (es) | 2019-09-25 | 2022-07-11 | Codiak Biosciences Inc | Composiciones de vesícula extracelular. |
| EP4034247A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| WO2021068866A1 (en) * | 2019-10-10 | 2021-04-15 | Beigene, Ltd. | Heterocyclic compounds as sting modulators |
| CN116813647B (zh) * | 2019-11-02 | 2025-08-01 | 上海凌达生物医药有限公司 | 一类含氮稠环类sting调节剂类化合物、制备方法和用途 |
| CN112940004B (zh) * | 2019-12-11 | 2022-07-12 | 中国科学院上海药物研究所 | 一种杂环化合物及其用途 |
| JP7662644B2 (ja) * | 2019-12-18 | 2025-04-15 | シーティーエックスティー・ピーティーワイ・リミテッド | 化合物 |
| CN113087668B (zh) * | 2019-12-23 | 2022-11-04 | 中国科学院上海药物研究所 | 一类苯并咪唑二聚体、其制备方法及用途 |
| CN113248475B (zh) * | 2020-02-11 | 2023-03-17 | 中国科学院上海药物研究所 | 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途 |
| BR112022015283A2 (pt) | 2020-03-06 | 2022-09-20 | Daiichi Sankyo Co Ltd | Conjugado anticorpo-fármaco incluindo derivados de dinucleotídeos cíclicos |
| US20230114434A1 (en) | 2020-03-13 | 2023-04-13 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
| EP4121450A2 (en) | 2020-03-20 | 2023-01-25 | Codiak BioSciences, Inc. | Extracellular vesicles for therapy |
| JP2023520513A (ja) | 2020-04-02 | 2023-05-17 | メルサナ セラピューティクス インコーポレイテッド | Ｓｔｉｎｇアゴニストを含む抗体薬物コンジュゲート |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | Method of cancer therapy |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| JPWO2022050300A1 (enExample) | 2020-09-02 | 2022-03-10 | ||
| CA3193264A1 (en) * | 2020-09-02 | 2022-03-10 | The Scripps Research Institute | Agonists of stimulator of interferon genes sting |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| US20240082389A1 (en) | 2020-09-23 | 2024-03-14 | Lonza Sales Ag | Methods of producing extracellular vesicles |
| EP4240488A1 (en) | 2020-11-09 | 2023-09-13 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| KR20230133331A (ko) | 2021-01-15 | 2023-09-19 | 씨젠 인크. | 면역조절 항체-약물 컨쥬게이트 |
| CN112920172B (zh) * | 2021-02-01 | 2022-03-22 | 厦门大学 | 一种干扰素刺激蛋白靶向化合物、其放射性标记物、及它们的制备方法与应用 |
| KR102881036B1 (ko) | 2021-02-17 | 2025-11-05 | 한국화학연구원 | 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| WO2022177307A1 (ko) * | 2021-02-17 | 2022-08-25 | 한국화학연구원 | 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| JP2024514707A (ja) | 2021-04-20 | 2024-04-02 | アンスティテュ・クリー | 免疫療法における使用のための組成物及び方法 |
| WO2022246597A1 (en) * | 2021-05-24 | 2022-12-01 | Forever Millets Limited | Imidazopyridine derivatives as sting agonists |
| US20240285755A1 (en) | 2021-05-24 | 2024-08-29 | Glaxosmithkline Biologicals Sa | Adjuvants |
| JP2024523453A (ja) * | 2021-06-25 | 2024-06-28 | ボルト バイオセラピューティクス、インコーポレーテッド | ビス－ベンゾイミダゾールｓｔｉｎｇアゴニスト免疫複合体及びその使用 |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023025256A1 (zh) * | 2021-08-26 | 2023-03-02 | 成都先导药物开发股份有限公司 | 一种适合作为抗体偶联药物效应分子的sting激动剂 |
| WO2023056468A1 (en) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Extracellular vesicle comprising cholesterol tagged sting-agonist |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
| KR20240115324A (ko) * | 2022-01-11 | 2024-07-25 | 주식회사 비씨켐 | Sting 작용제로서 융합된 헤테로아릴 히드록사메이트 |
| WO2023148129A1 (en) * | 2022-02-02 | 2023-08-10 | F. Hoffmann-La Roche Ag | Imidazole macrocycles for the treatment of autoimmune disease |
| KR20240150807A (ko) | 2022-02-22 | 2024-10-16 | 아라리스 바이오테크 아게 | 2개 이상의 페이로드를 포함하는 펩티드 링커 |
| JPWO2023167238A1 (enExample) | 2022-03-02 | 2023-09-07 | ||
| WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
| IL317957A (en) | 2022-07-05 | 2025-02-01 | Pfizer | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS |
| AU2023336004A1 (en) | 2022-08-29 | 2025-03-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including mutant fc region |
| WO2024076964A1 (en) * | 2022-10-03 | 2024-04-11 | Thomas Jefferson University | Pyrrolidine and imidazolidine based dna polymerase theta inhibitors and use thereof |
| WO2024074977A1 (en) | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
| WO2024084364A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Compounds for the treatment of cancer |
| WO2024105563A1 (en) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| WO2024182414A1 (en) | 2023-02-27 | 2024-09-06 | Biontech Us Inc. | Sting agonists containing hydrazide, hydrazine, and hydroxamic acid functional groups |
| WO2024180103A1 (en) | 2023-02-27 | 2024-09-06 | BioNTech SE | Sting agonists containing benzylic alcohol and benzylic amine functional groups |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| AU2024253142A1 (en) | 2023-04-05 | 2025-10-16 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024213979A1 (en) | 2023-04-10 | 2024-10-17 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2025012195A1 (en) * | 2023-07-10 | 2025-01-16 | F. Hoffmann-La Roche Ag | Bicyclic macrocycles for the treatment of autoimmune disease |
| US20250108048A1 (en) * | 2023-07-31 | 2025-04-03 | Sutro Biopharma, Inc. | Sting agonist compounds and conjugates |
| WO2025057126A1 (ko) * | 2023-09-15 | 2025-03-20 | 삼진제약주식회사 | Sting(인터페론 유전자 자극인자) 활성화제로서의 헤테로 고리 유도체 및 이를 포함하는 약학적 조성물 |
| EP4534147A1 (en) | 2023-10-05 | 2025-04-09 | Sulis Therapeutics ApS | Sting antagonist compounds |
| WO2025094035A1 (en) | 2023-11-01 | 2025-05-08 | Pfizer Inc. | Toll-like receptor agonists and conjugates thereof |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| EP1065213A3 (en) | 1999-07-02 | 2003-11-05 | Japan Tobacco Inc. | HCV polymerase suitable for crystal structure analysis and method for using the enzyme |
| CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| AU763356C (en) | 1999-12-27 | 2004-08-26 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| AU2001269695B2 (en) | 2000-05-19 | 2007-02-15 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| CA2417806C (en) | 2000-08-04 | 2011-05-10 | Corixa Corporation | New immunoeffector compounds |
| US6310224B1 (en) | 2001-01-19 | 2001-10-30 | Arco Chemical Technology, L.P. | Epoxidation catalyst and process |
| SI1355916T1 (sl) | 2001-01-22 | 2007-04-30 | Merck & Co Inc | Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| EP1378509A4 (en) | 2001-03-19 | 2009-03-25 | Ono Pharmaceutical Co | DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| EP1497469A4 (en) | 2002-04-04 | 2005-06-08 | Achillion Pharmaceuticals Inc | TEST FOR ASSESSING THE ACTIVITY OF COMPOUNDS AGAINST HCV USING A NOVEL DETECTION SYSTEM IN THE HCV REPLICIC |
| DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
| AU2003257419B2 (en) | 2002-06-13 | 2010-02-25 | Crucell Holland, B.V. | OX40 (CD134) receptor agonistic and therapeutic use |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| AR041816A1 (es) | 2002-10-24 | 2005-06-01 | Glaxo Group Ltd | Compuesto de acil-pirrolidina, su uso para preparar una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para prepararlo |
| BR0315937A (pt) | 2002-11-01 | 2005-09-13 | Viropharma Inc | Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo |
| ES2311755T3 (es) | 2002-12-13 | 2009-02-16 | Smithkline Beecham Corporation | Compuestos de ciclohexilo como antagonistas de ccrs. |
| CN1744899A (zh) | 2002-12-13 | 2006-03-08 | 史密丝克莱恩比彻姆公司 | 作为ccr5拮抗剂的哌啶衍生物 |
| ES2312856T3 (es) | 2002-12-13 | 2009-03-01 | Smithkline Beecham Corporation | Compuestos heterociclicos como antagonistas de ccr5. |
| ES2309400T3 (es) | 2002-12-13 | 2008-12-16 | Smithkline Beecham Corporation | Compuestos de pirrolidina y azetidina como antagonistas de ccr5. |
| JP2006514950A (ja) | 2002-12-13 | 2006-05-18 | スミスクライン ビーチャム コーポレーション | Ｃｃｒ５拮抗薬としてのシクロプロピル化合物 |
| AU2003300952A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Indane compounds as ccr5 antagonists |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| ZA200600424B (en) | 2003-08-01 | 2007-05-30 | Genelabs Tech Inc | Bicyclic imidazol derivatives against flaviviridae |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| WO2005070420A1 (en) | 2004-01-14 | 2005-08-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1h-benzimidazol-2-yl-benzamide derivatives and related compounds as itk inhibitors (interleukin-2-inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
| EP1711495A2 (en) | 2004-01-23 | 2006-10-18 | Amgen Inc. | Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer |
| KR20120091276A (ko) | 2004-02-20 | 2012-08-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이러스 폴리머라제 억제제 |
| EP1740192B1 (en) | 2004-03-15 | 2012-06-13 | David K. R. Karaolis | Cyclic dinucleotide for stimulating the immune of inflammatory response |
| WO2005105761A1 (en) | 2004-04-28 | 2005-11-10 | Arrow Therapeutics Limited | Morpholinylanilinoquinazo- line derivatives for use as antiviral agents |
| TW200600492A (en) | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| RS51794B (sr) | 2004-08-18 | 2011-12-31 | Pfizer Inc. | Inhibitori rnk zavisne rnk polimeraze hepatitis c virusa i kompozicije i tretmani koji ih koriste |
| GB0423673D0 (en) | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| US20070060589A1 (en) * | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| CA2607089A1 (en) | 2005-05-04 | 2006-11-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| AP2358A (en) | 2005-05-09 | 2012-01-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use. |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| SG10201809390QA (en) | 2005-05-10 | 2018-11-29 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| PL1907424T3 (pl) | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
| EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2737907A3 (en) | 2007-05-07 | 2014-11-05 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US8354509B2 (en) | 2007-06-18 | 2013-01-15 | Msd Oss B.V. | Antibodies to human programmed death receptor PD-1 |
| SI2851374T1 (sl) | 2007-12-14 | 2017-08-31 | Bristol-Myers Squibb Company | Vezavne molekule k humanemu ox40 receptorju |
| KR20100116206A (ko) | 2008-02-01 | 2010-10-29 | 다케다 야쿠힌 고교 가부시키가이샤 | Ｈｓｐ90 저해제로서의 옥심 유도체 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2009143039A2 (en) | 2008-05-19 | 2009-11-26 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| JP6087503B2 (ja) | 2008-09-26 | 2017-03-08 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途 |
| BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
| RU2017132160A (ru) | 2008-12-09 | 2019-02-08 | Дженентек, Инк. | Антитела к pd-l1 и их применение для усиления функции t-клеток |
| BRPI1012282A2 (pt) | 2009-03-27 | 2015-09-22 | Presidio Pharmaceuticals Inc | inibidores de anel fundidos da hepatite c. |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| RU2706200C2 (ru) | 2009-11-24 | 2019-11-14 | Медиммьюн Лимитед | Специфические связывающие агенты против в7-н1 |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011091446A1 (en) * | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| UY33288A (es) * | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| US8598156B2 (en) * | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| EA201690998A1 (ru) | 2010-05-17 | 2017-01-30 | Инкозен Терапьютикс Пвт. Лтд. | НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ |
| CN101898945B (zh) | 2010-07-27 | 2013-05-08 | 大连理工大学 | 盐析萃取发酵液中丙酮和丁醇的方法 |
| HRP20170568T1 (hr) | 2010-08-23 | 2017-06-30 | Board Of Regents, The University Of Texas System | Protutijela anti-ox40 i postupci za njihovu uporabu |
| US20140364617A1 (en) | 2010-12-15 | 2014-12-11 | Abbvie Inc. | Anti-viral compounds |
| EP2691419B1 (en) | 2011-03-31 | 2016-11-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies directed against icos and uses thereof |
| CA2843595C (en) | 2011-08-01 | 2022-10-18 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| CN103946238B (zh) | 2011-08-23 | 2016-10-12 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
| CA2907616A1 (en) | 2012-04-30 | 2013-11-07 | Glen N. Barber | Modulating immune responses |
| IL318221A (en) | 2012-05-15 | 2025-03-01 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting PD–1/PD–L1 signaling |
| AU2013271375B2 (en) | 2012-06-08 | 2018-03-22 | Aduro Biotech, Inc. | Compositions and methods for cancer immunotherapy |
| WO2014001464A1 (en) | 2012-06-27 | 2014-01-03 | 4Sc Discovery Gmbh | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
| EP2892928B1 (en) | 2012-09-03 | 2018-05-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies directed against icos for treating graft-versus-host disease |
| MX370848B (es) | 2012-10-04 | 2020-01-08 | Dana Farber Cancer Inst Inc | Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso. |
| CN105008381B (zh) | 2012-12-13 | 2018-08-07 | 艾杜罗生物科技公司 | 包含具有确定立体化学的环嘌呤二核苷酸的组合物及其制备和使用方法 |
| BR112015028341A2 (pt) | 2013-05-18 | 2017-07-25 | Aduro Biotech Inc | composições e métedos para ativação de "sinalização dependente de estimulador de gene interferon |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| US10227638B2 (en) | 2014-06-02 | 2019-03-12 | Base4 Innovation Ltd. | Nucleotide polymorphism detection method |
| CN106459131B (zh) * | 2014-06-04 | 2019-04-12 | 葛兰素史克知识产权开发有限公司 | 作为sting调节剂的环状二核苷酸 |
| EP3166974A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| EP3735986A1 (en) | 2015-03-23 | 2020-11-11 | Jounce Therapeutics, Inc. | Antibodies to icos |
| EA034786B1 (ru) | 2015-08-13 | 2020-03-20 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные соединения в качестве агонистов sting |
| MA52157A (fr) | 2015-12-03 | 2021-02-17 | Glaxosmithkline Ip Dev Ltd | Dinucléotides cycliques de purine utilisés comme modulateurs de sting |
| RU2018137389A (ru) * | 2016-04-07 | 2020-05-12 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Гетероциклические амиды, полезные в качестве модуляторов |
| UA123407C2 (uk) | 2016-04-07 | 2021-03-31 | Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед | Гетероциклічні аміди, придатні як модулятори протеїнів |
-
2017
- 2017-04-05 UA UAA201810983A patent/UA123407C2/uk unknown
- 2017-04-05 PL PL17716312.8T patent/PL3440076T3/pl unknown
- 2017-04-05 CR CR20200045A patent/CR20200045A/es unknown
- 2017-04-05 CN CN201811311714.9A patent/CN109608443B/zh active Active
- 2017-04-05 LT LTEPPCT/IB2017/051945T patent/LT3440076T/lt unknown
- 2017-04-05 AU AU2017247798A patent/AU2017247798C1/en active Active
- 2017-04-05 KR KR1020187032396A patent/KR102527784B1/ko active Active
- 2017-04-05 US US16/091,189 patent/US10981901B1/en active Active
- 2017-04-05 WO PCT/IB2017/051945 patent/WO2017175147A1/en not_active Ceased
- 2017-04-05 MX MX2020009948A patent/MX387353B/es unknown
- 2017-04-05 IL IL285702A patent/IL285702B/en unknown
- 2017-04-05 NZ NZ745957A patent/NZ745957A/en unknown
- 2017-04-05 SG SG11201808621TA patent/SG11201808621TA/en unknown
- 2017-04-05 MY MYPI2018703686A patent/MY189100A/en unknown
- 2017-04-05 SG SG10201900629VA patent/SG10201900629VA/en unknown
- 2017-04-05 UY UY0001037195A patent/UY37195A/es unknown
- 2017-04-05 JP JP2018552758A patent/JP6746712B2/ja active Active
- 2017-04-05 PE PE2018002322A patent/PE20181920A1/es unknown
- 2017-04-05 EP EP17716312.8A patent/EP3440076B1/en active Active
- 2017-04-05 ES ES17716312T patent/ES2921855T3/es active Active
- 2017-04-05 JO JOP/2017/0083A patent/JOP20170083B1/ar active
- 2017-04-05 PE PE2018001834A patent/PE20181884A1/es unknown
- 2017-04-05 SI SI201731184T patent/SI3440076T1/sl unknown
- 2017-04-05 PE PE2018002003A patent/PE20181919A1/es unknown
- 2017-04-05 EP EP22159533.3A patent/EP4032885A1/en active Pending
- 2017-04-05 RS RS20220734A patent/RS63462B1/sr unknown
- 2017-04-05 HR HRP20220936TT patent/HRP20220936T1/hr unknown
- 2017-04-05 PT PT177163128T patent/PT3440076T/pt unknown
- 2017-04-05 CN CN201780022379.8A patent/CN109071514B/zh active Active
- 2017-04-05 KR KR1020187031915A patent/KR102527786B1/ko active Active
- 2017-04-05 MX MX2020009947A patent/MX387354B/es unknown
- 2017-04-05 HU HUE17716312A patent/HUE058932T2/hu unknown
- 2017-04-05 CN CN202110799242.1A patent/CN113549110B/zh active Active
- 2017-04-05 SM SM20220339T patent/SMT202200339T1/it unknown
- 2017-04-05 CA CA3019630A patent/CA3019630A1/en active Pending
- 2017-04-05 MX MX2018012333A patent/MX379169B/es unknown
- 2017-04-05 CR CR20200044A patent/CR20200044A/es unknown
- 2017-04-05 SG SG10201900628RA patent/SG10201900628RA/en unknown
- 2017-04-05 DK DK17716312.8T patent/DK3440076T3/da active
- 2017-04-06 TW TW107147613A patent/TWI777014B/zh active
- 2017-04-06 TW TW111130004A patent/TWI868471B/zh active
- 2017-04-06 TW TW106111324A patent/TWI776806B/zh active
-
2018
- 2018-01-03 US US15/730,664 patent/US10189820B2/en active Active
- 2018-08-30 IL IL261482A patent/IL261482B/en unknown
- 2018-09-06 IL IL261657A patent/IL261657B/en unknown
- 2018-09-13 AU AU2018229498A patent/AU2018229498C1/en active Active
- 2018-09-13 AU AU2018229497A patent/AU2018229497C1/en active Active
- 2018-10-04 CO CONC2018/0010727A patent/CO2018010727A2/es unknown
- 2018-10-04 DO DO2018000217A patent/DOP2018000217A/es unknown
- 2018-10-05 CL CL2018002850A patent/CL2018002850A1/es unknown
- 2018-10-05 PH PH12018502151A patent/PH12018502151B1/en unknown
- 2018-10-11 PH PH12018502179A patent/PH12018502179A1/en unknown
- 2018-10-15 PH PH12018502202A patent/PH12018502202A1/en unknown
- 2018-11-20 CL CL2018003290A patent/CL2018003290A1/es unknown
- 2018-11-20 CL CL2018003291A patent/CL2018003291A1/es unknown
-
2020
- 2020-01-30 AU AU2020200692A patent/AU2020200692C1/en active Active
- 2020-01-30 DO DO2020000018A patent/DOP2020000018A/es unknown
- 2020-01-30 DO DO2020000019A patent/DOP2020000019A/es unknown
- 2020-02-26 JP JP2020030908A patent/JP6861307B2/ja active Active
-
2021
- 2021-01-25 US US17/156,893 patent/US11365190B2/en active Active
- 2021-03-26 JP JP2021054203A patent/JP7119158B2/ja active Active
-
2022
- 2022-05-17 US US17/663,749 patent/US11970480B2/en active Active
- 2022-08-01 JP JP2022122895A patent/JP7466596B2/ja active Active
- 2022-08-15 IL IL295649A patent/IL295649B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285702B (en) | Heterocyclic amides are useful as protein modulators | |
| PL3577110T3 (pl) | Związki podstawione 8-oksetan-3-ylo-3,8-diazabicyklo[3.2.1]oktan-3-ylem jako inhibitory hiv | |
| PH12018502136A1 (en) | Heterocyclic amides useful as protein modulators | |
| EP3687543A4 (en) | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | |
| EP3349968A4 (en) | PRINT HEAD MODULE WITH ADJUSTABLE Z-AXIS FOR GENERATIVE MANUFACTURING SYSTEM | |
| IL261046A (en) | Transduced 3,2,1-triazoles as selective nmda modulators for nr2b | |
| WO2018006074A3 (en) | Compounds and methods for modulating rna function | |
| EP3344917A4 (en) | SQUARE SUBPIXELDLISHING MULTI-VIEWING DISPLAY WITH DISPLACED MULTI-RADIANT BENDING GRIDS | |
| PH12016500494A1 (en) | Heterocycle-substituted bicyclic azole pesticides | |
| WO2016044676A3 (en) | Novel feline erythropoietin receptor agonists | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| FI3692023T3 (fi) | Bentsotiatsoliyhdisteitä ja menetelmiä niiden käyttämiseksi neurodegeneratiivisten häiriöiden hoitoon | |
| IN2015DN01331A (enExample) | ||
| GB2577981B (en) | Methods, products & Uses relating thereto | |
| PT3418275T (pt) | Composto inovador de tiofeno substituído em 2,3,5 como inibidor de proteína quinase | |
| EP3303323A4 (en) | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists | |
| EP3677119A4 (en) | HERBICIDE FORMULATION IN THE FORM OF A MICROEMULSION | |
| WO2017013498A3 (en) | Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions | |
| GB201813648D0 (en) | Methods, products & uses relating thereto | |
| IL274715A (en) | A method for producing (3s)-3-(4-chloro-3-{[(2s,3r)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3- Cyclopropylpropanoic acid and its crystalline form for use as a pharmaceutical ingredient | |
| WO2016159576A3 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
| WO2016042171A3 (en) | A xanthene compound, and a colorant comprising the same | |
| EP3658354A4 (en) | Controlled cooling for print heads | |
| WO2018115877A3 (en) | Rumen derived antimicrobial peptides | |
| FI3878444T3 (fi) | (n-(2-((2-bentsyylifenyyli)amino)-2-oksoetyyli)-l-naftamidi) syöpälääkeaineena |